RACE AND ‘OMIC’ DATA IN GLIOMA: A SYSTEMATIC REVIEW OF CONTEMPORARY RESEARCH TO EXPLORE THE DIGITAL DIVIDE

Résumé fourni par la source

Abstract AIMS Specific genetic mutations in glioma can predict prognosis as well as predict the potential benefits of particular treatments. There is an important and urgent need to establish whether current reporting of race and ethnicity data in contemporary studies generating new genome-scale sequencing data for gliomas is adequate. We aimed to provide a snapshot describing the current state of racial and ethnic representation in recently published studies which, have generated de novo genome-scale sequencing data from glioma samples. METHODS We searched PubMed, Embase, Web of Science, and Scopus and systematically reviewed articles published be- tween January and November 2023 reporting de novo genome-scale sequencing data generated using samples from patients diagnosed with a glioma (according to WHO 2021 criteria) to characterise the reporting and com- position of race and ethnicity data. RESULTS Thirty-five studies involving 5,601 patients were analysed. Race or ethnicity data was reported in only 3 studies (8.6%), of which none provided omic data in a format that could be stratified by race or ethnicity. Reporting varied by continent with all 3 studies including race or ethnicity data based in North America. Where racial data was available, we found that samples used for genome-scale characterisation came from patients reported as being White in 91.1% cases (41 patients), with 6.7% (3 patients) reported as Black and 2.2% (1 patient) as Hispanic. CONCLUSION Race and ethnicity data is exquisitely underreported in contemporary glioma studies generating genome-scale omic data, and where it is reported, the data is typically not shared in a format that makes stratification of genetic variants and their impact by ethnicity possible. Improved reporting of race and ethnicity data, along- side initiatives to broaden representation, are required to enhance our understanding of glioma biology across different populations and ultimately, provide more equitable advancements in healthcar

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.